Axplora`s Ursodeoxycholic Receives 5-Year Renewed Registration
Aurobindo's Generic Ursodiol Receives Approval in the U.S.
RICHMOND, Va., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Bon Secours Liver Institute of Richmond is enrolling participants into RESPONSE, a global phase 3 clinical research study evaluating the safety and efficacy of seladelpar, an investigational drug for people already diagnosed with PBC who have been using ursodeoxycholic acid (also known as UDCA or ursodiol) but have not achieved the recommended treatment goal or cannot tolerate UDCA. PBC is a chronic, serious and potentially life-threatening liver disease.
SEATTLE, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Liver Institute Northwest is enrolling participants into RESPONSE, a global phase 3 clinical research study evaluating the safety and efficacy of seladelpar, an investigational drug for people already diagnosed with PBC who have been using ursodeoxycholic acid (also known as UDCA or ursodiol) but have not achieved the recommended treatment goal or cannot tolerate UDCA. PBC is a chronic, serious and potentially life-threatening liver disease.
The Union commerce ministry has initiated anti-dumping probe against ursodeoxycholic acid, a chemical used in drug industry, imported from China and South Korea, following a complaint filed by Arch Pharma Labs.
SAN ANTONIO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- The Texas Liver Institute is enrolling participants into RESPONSE, a global phase 3 clinical research study evaluating the safety and efficacy of seladelpar, an investigational drug for people already diagnosed with PBC who have been using ursodeoxycholic acid (also known as UDCA or ursodiol) but have not achieved the recommended treatment goal or cannot tolerate UDCA. PBC is a chronic, serious and potentially life-threatening liver disease.
SAN ANTONIO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pinnacle Clinical Research, PLLC is enrolling participants into RESPONSE, a global phase 3 clinical research study evaluating the safety and efficacy of seladelpar, an investigational drug for people already diagnosed with PBC who have been using ursodeoxycholic acid (also known as UDCA or ursodiol) but have not achieved the recommended treatment goal or cannot tolerate UDCA. PBC is a chronic, serious and potentially life-threatening liver disease.
SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--Phase 2 clinical results with HTD1801, a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM), have been published online in Nature Communications by HighTide Therapeutics.
Vgyaan`s Generic Ursodiol Receives Approval In US
New Delhi: Strides Pharma Science on Friday said its step-down subsidiary has received approval from the US health regulator to market Ursodiol tablets, used for treatment of patients with primary biliary cirrhosis (PBC).